PUNE: Advinus Therapeutics Ltd., the TATA promoted pharmaceutical R&D company, announced that it has reached the third milestone in its research and development collaboration with Takeda Pharmaceutical Company Limited. The achievement of this milestone highlights the success of the collaboration.
In October 2012, Advinus and Takeda announced a multi-year, multi-project collaboration in the area of drug discovery. In this collaboration, Advinus is responsible for carrying out all the research required to identify candidate molecules for clinical development in several therapeutic areas while Takeda is responsible for the development and commercialization of these candidates.
In each of the previous two years, Advinus has met predetermined milestones. The achievement of the third milestone underscores the rapid progress of the research programs over the past year, a result of the innovative solutions and the speed and quality of Advinus’ efforts supported by Takeda’s guidance and highly interactive engagement.
“The achievement of the third milestone by Advinus’ young and talented scientists is a clear demonstration of how an effective partnership could deliver novel and effective candidates for drug development in a cost effective manner,” said Kasim Mookhtiar, CEO & MD of Advinus.